Manuel Hidalgo 🇪🇸 🇺🇸

Professor of Medicine. co Director GI Cancer Center at NYU Langone. Pancreatic cancer researcher. Opinions are mine.

[Anirban Maitra @Aiims1742]

Excited at the launch of the @Perlmutter_CC KRAS Excellence Initiative (KRAS-X), a multidisciplinary effort focused on advancing clinical trials & translational research to improve care for patients with KRAS-mutated cancers. More details below:
https://t.co/qGXqK2e3Oc

[Anirban Maitra @Aiims1742]

On this week’s @statnews podcast The Readout Loud with @adamfeuerstein @elaineywchen & @ADeAngelis_bio, @Perlmutter_CC Chief of GI oncology @md_oberstein talks about Revolution Medicines phase 3 data in #PancreaticCancer #AACR26
@nyulangone @DrMhidalgo
https://t.co/qdcIqsMC5F

[Manuel Hidalgo 🇪🇸 🇺🇸 @DrMhidalgo]

@KingTunde_SZN 36

[Manuel Hidalgo 🇪🇸 🇺🇸 @DrMhidalgo]

@Gosleepriya 18

[Manuel Hidalgo 🇪🇸 🇺🇸 @DrMhidalgo]

@Cairo_xprsk 21

[Anirban Maitra @Aiims1742]

There is a lot happening on advancing clinical trials in solid tumor cell therapy at @Perlmutter_CC @nyulangone and @salmanpunekar is at the forefront of these efforts.
https://t.co/Ug6Jb9M7N8
@JohnPLeonardMD @DrOscarLahoud

[Anirban Maitra @Aiims1742]

A hugely important leadership position at @nyulangone is open:
Chair of Pathology
https://t.co/OA9fnR5muf
At a pivotal moment where we are 100% digital in our clinical practice, with enormous opportunities for improving healthcare delivery and building translational research!

[Anirban Maitra @Aiims1742]

Congratulations Bob!

[ABC.es @abc_es]

Muere el doctor Hernán Cortes Funes, pionero de la oncología moderna https://t.co/kjg9gnbYH3

[SEOM @_SEOM]

Desde SEOM queremos transmitir nuestro más sentido pésame y trasladar un abrazo enorme a los familiares y amigos del Dr. Hernán Cortés Funes

El Dr. Hernán Cortés Funes fue presidente de la Sociedad Española de Oncología Médica (SEOM) entre 1987 y 1989 y uno de los pioneros en el impulso de la Oncología Médica en nuestro país

[Umamaheswar Duvvuri MD PhD @duvvuri_md]

Deeply grateful to the dedicated staff (Residents, Nurses & Faculty) at @nyulangone & @nyugrossman who have braved the storm to provide exceptional care!
I am honored to be a part of this exceptional team!

[Anirban Maitra @Aiims1742]

Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas (cystic precursor lesions to #PancreaticCancer)
https://t.co/VfH6s9ZMp5
A review written by past and present members of the Maitra lab, including two (Makino & Thege) that now have their own labs.

[Anirban Maitra @Aiims1742]

Are Hedgehog inhibitors making a comeback in #PancreaticCancer, this time with nuanced sequencing and combination regimen?
Preprint of 1st line clinical trial in advanced PDAC, @DrMhidalgo @Perlmutter_CC (in collaboration with @Val_LeBleu @rkalluriMDPhD):
https://t.co/dpNr93cnsd

[John P. Leonard, MD @JohnPLeonardMD]

We are hiring:
Stem Cell Transplant/Cellular Therapy/Heme Malignancy Faculty Physicians/Director

Will be at @ASH_hematology meeting and happy to meet with interested potential candidates - just contact me directly #ASH25 #ASH2025

https://t.co/A4EZOz8KJM

[Bruno Bockorny MD FACP @BrunoBockorny]

TRYBECA-1 Trial -- largest randomized trial in the 2nd line of PDAC ever conducted. Unfortunately, adding eryaspase to chemo (gem/nab or nal-iri/5-FU) in #PancreaticCancer did not improve OS, PFS, or ORR (median OS 7.5 mo vs 6.7 mo; HR 0.92). Toxicity was similar. @DrMhidalgo

[John P. Leonard, MD @JohnPLeonardMD]

We are recruiting!  Feel free to DM/contact me!
Heme Malignancies/Stem Cell Transplant/Cell Therapy Assist/Assoc/Full Professor Faculty in Heme Malignancies and/or Cellular Therapy/Stem Cell Transplant (including leadership roles) primarily at NYU Langone Hospital-Long Island

[Anirban Maitra @Aiims1742]

Join @NYUDocs Chiefs Rounds to hear @DrMhidalgo and me talk about the @Perlmutter_CC @nyulangone Gastrointestinal Cancer Center!
#PancreaticCancer #ColorectalCancer

[Bruno Bockorny MD FACP @BrunoBockorny]

TRYBECA-1 Trial -- Adding eryaspase to 2nd-line chemo (gem/nab or nal-iri/5-FU) in #PancreaticCancer did not improve OS, PFS, or ORR (median OS 7.5 mo vs 6.7 mo; HR 0.92). Toxicity was similar. @DrMhidalgo @BIDMC_CancerCtr
https://t.co/BwsSvHvDDn

[Dr. Despina Siolas, MD, PhD @DrDespina123]

1/2 At the #AACRPan25 meeting, I was grateful to reconnect with the extraordinary NYC-based pancreatic cancer research & clinical community including mentors whose guidance continues to inspire my work.

#PancreaticCancer #TranslationalResearch #Mentorship

[Dr. Despina Siolas, MD, PhD @DrDespina123]

Also excited to welcome @Aiims1742 to the NYC fold — looking forward to new collaborations that will strengthen our collective efforts to advance research and improve outcomes for patients.

@drallysonocean @DrMhidalgo
PaulOberstein
#Collaboration #AACRPan25